CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
omalizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00382148
NCT00382148Phase 2Completed
CompareCT.gov

A Phase IIb, Open-Label Study of Xolair (Omalizumab) in Peanut-Allergic Subjects Randomized to Study Drug in Study Q2788g (TOPS)

Genentech, Inc.·interventional·Posted Sep 28, 2006·Updated Jun 2, 2026

In Brief

A Phase 2 clinical trial evaluating omalizumab for Peanut Hypersensitivity. Completed, enrolled 11 participants.

Detailed Summary

This is a Phase IIb, multicenter, open-label study available to active (Xolair) and control (placebo) subjects who have completed their final visit (or early termination visit, if applicable) for Study Q2788g, who meet the eligibility criteria of this study, and who provide consent to participate in this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeanut Hypersensitivity
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 28, 2006
Enrollment StartNov 1, 2006
Primary CompletionJun 28, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.8 years ago

Interventions

omalizumabdrug

Subcutaneous repeating dose